obiltoxaximab April 12, 2017 obiltoxaximab Trade Name Anthim Orphan Indication Exposure to B. anthracis spores USA Market Approval USA USA Designation Date 2006-06-09 00:00:00 Sponsor Elusys Therapeutics, Inc.;25 Riverside Drive, P.O. Box 102;Pine Brook, New Jersey, 07058
